MENLO PARK, Calif., Oct. 19 /PRNewswire/ --
ORATEC Interventions, Inc. (Nasdaq: OTEC) today announced that two peer
reviewed articles in the October 2000 edition of SPINE journal show the
effectiveness of the company's SpineCATH IntraDiscal ElectroThermal Therapy
(IDET(TM)) system with a minimum one year follow-up.
The studies report that the majority of patients treated with IDET
experience a significant reduction in pain and improvement in physical
function. These clinical results are consistent with other research that has
been previously published or presented on IDET. The company believes that
these additional peer reviewed journal articles will provide payors and health
care providers further support in offering IDET to their customers and
Studies Show Consistent Results
The first article discusses a case-control study which was conducted by
Michael Karasek, M.D., past president of the International Spinal Injection
Society (ISIS) and chairman of Sacred Heart Medical Center's Pain Department
in Eugene, Oregon, and Nikolai Bogduk, M.D., of the Newcastle Bone and Joint
Institute, University of Newcastle, in Australia.
"Twelve-Month Follow-Up of a Controlled Trial of Intradiscal Thermal
Anuloplasty for Back Pain Due to Internal Disc Disruption" compared
36 patients treated with IDET and a control group of 17 patients treated with
rehabilitation therapy. The two groups suffered from low back pain for an
average of two and one-half years.
One year after undergoing treatment, 60 percent of the IDET patients
reported both pain relief of 50 percent or greater and their return to work.
In contrast, only six percent of the control group experienced the same level
of pain relief.
The second article reports on a prospective study titled "Intradiscal
Electrothermal Treatment for Chronic Discogenic Low Back Pain: A Prospective
Outcome Study with Minimum 1-Year Follow-Up" and was co-authored by Jeff Saal,
M.D., who is past president of the North American Spine Society (NASS), and
Joel Saal, M.D. They are assistant clinical professors at Stanford University
School of Medicine in Palo Alto, California.
Their study included 62 patients who had chronic, unremitting low back
pain for an average of 5 years, and were unresponsive to non-operative care,
such as physical therapy and steroid injections. Each patient had been
offered the choice of chronic pain management, spinal fusion surgery, or the
minimally invasive IDET procedure.
An average of 16 months after treatment, more than 70 percent of the
study's patients showed significant decreases in pain and increases in
activity. In addition, the study noted, "Ninety-seven percent (97%) of the
private pay patients and 83% of the worker's compensation patients returned to
Dr. Jeff Saal will be presenting the latest two year follow-up data at the
NASS meeting in New Orleans on Thursday, October 26.
Reprints of the two SPINE articles will be available from ORATEC by
telephone at 888-996-1996 or e-mail at firstname.lastname@example.org.
ORATEC Interventions develops and markets innovative medical devices that
use controlled thermal energy to treat spine and joint disorders. The company
currently markets two minimally invasive systems, the SpineCATH IDET system to
treat chronic low back pain caused by degenerative disc disease and the
ElectroThermal Arthroscopy System to treat joint disorders. Its proprietary
systems use heat to modify, cut, or remove damaged or stretched soft tissue.
The company markets its products to orthopedic surgeons, neurosurgeons, and
pain management specialists. More than 2,700 physicians have performed over
185,000 procedures using ORATEC's technologies.
Except for historical information, the statements in this news release are
forward-looking statements involving risks and uncertainties that could cause
actual results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not limited
to, the need for physicians to support the use of the company's products, the
need to establish reimbursement from payors, the company's lack of long term
clinical results, the need for market acceptance of the company's products,
the company's need to train physicians, and the company's need to comply with
FDA and other regulations. Further information regarding these and other
risks is included in the company's report on Form 10-Q, filed with the SEC.
CONTACT: Nancy V. Westcott, Chief Financial Officer and Vice President
Administration, of ORATEC Interventions, Inc., 650-369-9904, or fax,
650-369-9905, or email@example.com.
SOURCE ORATEC Interventions, Inc.